Affiliation:
1. Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy
2. Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
Abstract
Cystic fibrosis (CF) is a high-prevalence disease characterized by significant lung remodeling, responsible for high morbidity and mortality worldwide. The lung structural changes are partly due to proteolytic activity associated with inflammatory cells such as neutrophils and macrophages. Matrix metalloproteases (MMPs) are the major proteases involved in CF, and recent literature data focused on their potential role in the pathogenesis of the disease. In fact, an imbalance of proteases and antiproteases was observed in CF patients, resulting in dysfunction of protease activity and loss of lung homeostasis. Currently, many steps forward have been moved in the field of pharmacological treatment with the recent introduction of triple-combination therapy targeting the CFTR channel. Despite CFTR modulator therapy potentially being effective in up to 90% of patients with CF, there are still patients who are not eligible for the available therapies. Here, we introduce experimental drugs to provide updates on therapy evolution regarding a proportion of CF non-responder patients to current treatment, and we summarize the role of MMPs in pathogenesis and as future therapeutic targets of CF.
Subject
Molecular Biology,Biochemistry
Reference95 articles.
1. Gruppo di lavoro RIFC. Registro italiano Fibrosi Cistica (RIFC). Rapporto 2019-2020 [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020];Campagna;Epidemiol. Prev.,2022
2. Cystic Fibrosis Foundation (2020, August 14). 2018 Patient Registry: Annual Data Report. Available online: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf.
3. Cystic fibrosis;Freedman;Lancet,2009
4. Cystic fibrosis transmembrane conductance regulator (CFTR): Making an ion channel out of an active transporter structure;Linsdell;Channels,2018
5. New horizons in the treatment of cystic fibrosis;Cuthbert;Br. J. Pharmacol.,2011
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献